Abstract
Methods: RITAZAREM was an international randomised controlled, open-label, superiority trial that recruited 188 patients at the time of an AAV relapse from 29 centres in seven countries between April 2013 and November 2016. All patients received rituximab and glucocorticoids to reinduce remission. Patients achieving remission by 4 months were randomised to receive rituximab intravenously (1000 mg every 4 months, through month 20) (85 patients) or azathioprine (2 mg/kg/day, tapered after month 24) (85 patients) and followed for a minimum of 36 months. The primary outcome was time to disease relapse (either major or minor relapse).
Results: Rituximab was superior to azathioprine in preventing relapse: HR 0.41; 95% CI 0.27 to 0.61, p
Conclusions: Following induction of remission with rituximab, fixed-interval, repeat-dose rituximab was superior to azathioprine for preventing disease relapse in patients with AAV with a prior history of relapse.
Original language | English |
---|---|
Pages (from-to) | 937-944 |
Number of pages | 8 |
Journal | Annals of the Rheumatic Diseases |
Volume | 82 |
Issue number | 7 |
Early online date | 23 Mar 2023 |
DOIs | |
Publication status | Published - Jul 2023 |
Bibliographical note
Funding:The RITAZAREM trial was supported by grant number 18706 from Arthritis Research UK (now Versus Arthritis) and by Roche/Genentech (MA28150). Roche/Genentech also provided rituximab for the study. The Vasculitis Clinical Research Consortium (VCRC) is part of the United States National Institutes of Health Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC has received funding from NCATS, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54 AR057319), the National Center for Research Resources (U54 RR019497). The Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan. RS and DJ were also supported by the National Institute for Health Research, Cambridge Biomedical Research Centre and the Cambridge Clinical Trials Unit.